<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5805">
  <stage>Registered</stage>
  <submitdate>12/02/2016</submitdate>
  <approvaldate>12/02/2016</approvaldate>
  <nctid>NCT02724228</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate Long-Term Safety, Tolerability, &amp; Efficacy of BMN 111 in Children With Achondroplasia (ACH)</studytitle>
    <scientifictitle>A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With Achondroplasia</scientifictitle>
    <utrn />
    <trialacronym>ACH</trialacronym>
    <secondaryid>2015-004004-30</secondaryid>
    <secondaryid>111-205</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Achondroplasia</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMN 111

Experimental: BMN 111 - Subcutaneous Injection - 111-205 is an open-label, extension study. Subjects receive the same stable dose of BMN 111 received upon completion of the 111-202 study. BMN 111 will be administered in one of the following daily dosing regimens: 15 µg/kg, 30 µg/kg, up to 60 µg/kg daily.


Treatment: drugs: BMN 111
BMN 111 will be administered daily for up to 260 weeks.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] - Number of study participants with treatment-emergent adverse events.
Number of study participants with treatment-emergent serious adverse events</outcome>
      <timepoint>260 Weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Growth Velocity [Efficacy] - Annualized growth velocity (cm/yr)</outcome>
      <timepoint>260 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Growth Parameters (Efficacy) - Height standard score (Z-score)</outcome>
      <timepoint>260 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body Proportions (Efficacy) - Upper-to-lower body segment ratio</outcome>
      <timepoint>260 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Have completed 24 months of BMN 111 treatment in Study 111-202.

          -  Parent(s) or guardian(s) are willing and able to provide written, signed informed
             consent.

          -  If sexually active, willing to use a highly effective method of contraception while
             participating in the study.

          -  Females &gt;= 10 years old or who have started menses must have a negative pregnancy test
             at baseline and be willing to have additional pregnancy tests during the study

          -  Willing and able to perform all study procedures as physically possible

          -  Parents/caregivers willing to administer daily injections to the subjects and complete
             the required training.</inclusivecriteria>
    <inclusiveminage>7</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>16</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Requires any investigational agent prior to completion of study period.

          -  Have a condition or circumstance that, in the view of the Investigator, places the
             subject at high risk for poor treatment compliance or for not completing the study.

          -  Concurrent disease or condition that, in the view of the Investigator, would interfere
             with study participation or safety evaluations for any reason.

          -  Permanently discontinued BMN 111 during the 111-202 study.

          -  Subject is pregnant.

          -  Current chronic therapy with restricted medications.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Murdoch Children's Research Institute - Parkville</hospital>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>BioMarin Pharmaceutical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety,
      Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective
      is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in
      children with ACH who have completed two years of treatment in the 111-202 study.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02724228</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director, MD</name>
      <address>BioMarin Pharmaceutical</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>